CARLYN PENTZIEN: Open Payments
NPI 1124534516 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$342 in 16 payments from 6 companies in 2025. Trend: 2023 $184 · 2024 $228 · 2025 $342
Food & beverage: $342
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 5 | $115 |
| CooperSurgical, Inc. | 3 | $79 |
| Octapharma USA, Inc. | 2 | $50 |
| Astellas Pharma US Inc | 2 | $36 |
| Biogen, Inc. | 2 | $33 |
| Exeltis, USA Inc. | 2 | $30 |
Products named: MYFEMBREE, Paragard T 380A, FIBRYGA, Veozah, ZURZUVAE, SLYND.
Industry payments across NE — which companies pay providers there.
